--- title: "Weekly Recap | Abbott Laboratories -3.58%, dual-sensing device wins FDA nod" type: "News" locale: "en" url: "https://longbridge.com/en/news/297386580.md" description: "Abbott finished the week at $112.47, down 3.58%, while the S&P 500 gained 0.49% — an underperformance of about 4.07 percentage points. The tape had a fade-the-rally character: it opened Monday at $116.28, touched a weekly high of $117.34, then slid over four sessions to a low of $111.11 on Thursday before a small bounce on Friday. The week’s amplitude was 5.36%, with average daily volume of 7.26m shares, about 31% below the 60-day median — a quiet tape." datetime: "2026-08-29T05:10:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297386580.md) - [en](https://longbridge.com/en/news/297386580.md) - [zh-HK](https://longbridge.com/zh-HK/news/297386580.md) generator: "portal-rs" --- # Weekly Recap | Abbott Laboratories -3.58%, dual-sensing device wins FDA nod ## The Week Abbott finished the week at $112.47, down 3.58%, while the S&P 500 gained 0.49% — an underperformance of about 4.07 percentage points. The tape had a fade-the-rally character: it opened Monday at $116.28, touched a weekly high of $117.34, then slid over four sessions to a low of $111.11 on Thursday before a small bounce on Friday. The week’s amplitude was 5.36%, with average daily volume of 7.26m shares, about 31% below the 60-day median — a quiet tape. ## Key Events The most concrete progress came on the product side. On Tuesday 25 August, Abbott received FDA authorisation for the world’s first dual glucose-ketone continuous sensing technology for people with diabetes; on Wednesday 26 August, the wearable device formally gained approval, making it one of the more closely followed med-tech headlines of the week. On Thursday 27 August, the next-generation Amulet 360 left atrial appendage closure device received CE mark for stroke prevention in atrial fibrillation. Industry-wise, there was news of rising cyber attacks against US companies, though that reads as background rather than a company-specific driver. Among positioning disclosures, Principal Financial Group, TD Asset Management and Heritage Trust all reported routine changes. Separately, on Friday 28 August, CEO Robert B. Ford disposed of about $46.17m in common shares. ## Analyst Ratings Across 28 institutions covering Abbott, 17 rate it buy, 4 rate it overweight, 6 rate it hold, and 1 has no opinion, with no sell or underweight ratings. The consensus rating is buy, with a consensus target of $120.20, about 6.87% above the latest price of $112.47. The target range runs from $103 to $135, a spread of about $32, reflecting moderate disagreement. Abbott ranks 7th out of 141 names in the medical-device industry by analyst rating. ## The Week Ahead A dense macro calendar awaits: the Dallas Fed manufacturing index on Monday 31 August, then S&P Global manufacturing PMI, ISM manufacturing PMI and JOLTS job openings on Tuesday 1 September, followed by ADP employment, factory orders and EIA crude inventories on Wednesday 2 September. ISM manufacturing PMI carries a prior of 55.6 and a forecast of 55.2, while ADP employment has a prior of 44 and a forecast of 47 — both useful signals on the US economy’s trajectory. For Abbott itself, the commercial ramp of the newly authorised dual-sensing device and the European rollout of the Amulet 360 after CE mark are likely to stay in focus. ## In Short Abbott pulled back from near record highs this week and lagged the market, even as two product milestones — FDA authorisation of dual glucose-ketone sensing and CE mark for the Amulet 360 — landed. The consensus rating stays at buy, with the consensus target nearly 7% above spot. On valuation, the stock trades around 36x P/E and 3.83x book, on the higher side of its own range. In the latest session, retail flow leaned net seller while large and mid-size flows were mixed, consistent with the sideways-to-lower tone. What matters next is the pace of commercial execution on those new products and whether the macro data shift sentiment across healthcare names — the near-term direction hinges on which of those two forces dominates. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) ## Related News & Research - [Abbott to pay $384 million over contaminated infant formula allegations, US Justice Dept says](https://longbridge.com/en/news/298950554.md) - [STEIN MITCHELL ATTORNEYS REPRESENT WHISTLEBLOWERS IN NEARLY $385 MILLION ABBOTT INFANT FORMULA SETTLEMENT](https://longbridge.com/en/news/298961296.md) - [Abbott agrees to settle DOJ lawsuit over baby formula plant contamination](https://longbridge.com/en/news/299081753.md) - [Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall | ABT Stock News](https://longbridge.com/en/news/298942114.md) - [Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms](https://longbridge.com/en/news/298316210.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**